All Outputs (2)

Plasma cells: a feasible therapeutic target in pulmonary fibrosis? (2022)
Journal Article
Goodwin, A. T., Noble, P. W., & Tatler, A. L. (2022). Plasma cells: a feasible therapeutic target in pulmonary fibrosis?. European Respiratory Journal, 60(5), Article 2201748. https://doi.org/10.1183/13993003.01748-2022

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterised by the irreversible replacement of normal lung parenchyma with stiff scar tissue. The prognosis of IPF is very poor, with a median survival worse than many canc... Read More about Plasma cells: a feasible therapeutic target in pulmonary fibrosis?.

Lysyl oxidase like 2 is increased in asthma and contributes to asthmatic airway remodelling (2022)
Journal Article
Ramis, J., Middlewick, R., Pappalardo, F., Cairns, J. T., Stewart, I. D., John, A. E., …Tatler, A. L. (2022). Lysyl oxidase like 2 is increased in asthma and contributes to asthmatic airway remodelling. European Respiratory Journal, 60(1), Article 2004361. https://doi.org/10.1183/13993003.04361-2020

BACKGROUND: Airway smooth muscle (ASM) cells are fundamental to asthma pathogenesis, influencing bronchoconstriction, airway hyperresponsiveness and airway remodelling. The extracellular matrix (ECM) can influence tissue remodelling pathways; however... Read More about Lysyl oxidase like 2 is increased in asthma and contributes to asthmatic airway remodelling.